2022
Relative contribution of low-density and asymptomatic infections to Plasmodium vivax transmission in the Amazon: pooled analysis of individual participant data from population-based cross-sectional surveys
Ferreira MU, Corder RM, Johansen IC, Kattenberg JH, Moreno M, Rosas-Aguirre A, Ladeia-Andrade S, Conn JE, Llanos-Cuentas A, Gamboa D, Rosanas-Urgell A, Vinetz JM. Relative contribution of low-density and asymptomatic infections to Plasmodium vivax transmission in the Amazon: pooled analysis of individual participant data from population-based cross-sectional surveys. The Lancet Regional Health - Americas 2022, 9: 100169. PMID: 35663000, PMCID: PMC9161731, DOI: 10.1016/j.lana.2021.100169.Peer-Reviewed Original ResearchIndividual participant dataPolymerase chain reactionClinical manifestationsParasite densityMosquito infectionMalaria transmissionPopulation-based cross-sectional surveyParticipant dataMalaria elimination strategiesPopulation-based surveyHigh parasite densityCross-sectional surveyInfected childrenClinical symptomsAsymptomatic infectionUS National InstitutesAsymptomatic carriersParasite carriersInfectious reservoirVivax transmissionInfectionFundação de Amparo à PesquisaChain reactionNational InstituteElimination strategy
2021
PvMSP8 as a Novel Plasmodium vivax Malaria Sero-Marker for the Peruvian Amazon
Villasis E, Garro K, Rosas-Aguirre A, Rodriguez P, Rosado J, Gave A, Guzman-Guzman M, Manrique P, White M, Speybroeck N, Vinetz JM, Torres K, Gamboa D. PvMSP8 as a Novel Plasmodium vivax Malaria Sero-Marker for the Peruvian Amazon. Pathogens 2021, 10: 282. PMID: 33801386, PMCID: PMC7999794, DOI: 10.3390/pathogens10030282.Peer-Reviewed Original ResearchSerological responsePopulation-based cross-sectional surveyRecent malaria exposureMerozoite surface protein 8Non-exposed individualsCross-sectional surveyMalaria control effortsTime of surveyPV exposureMalaria exposureIgG antibodiesTransmission settingsPV infectionGood biomarkerRecent exposurePast monthIgGPlasma samplesProtein 8Second evaluationExposureFirst evaluationIndividualsLuminexCohort